The Prostate Biobank is organized under the “Register and biobank for urologic diseases” at Department of Urology, Oslo University Hospital. The Prostate Biobank is managed by a scientific board headed by Prof. Kristin Austlid Taskén, Institute for Cancer Research. This Board also serves as Data Access Committee, and manages project applications.
The Prostate Biobank Research groups and The Prostate Biobank is a collaborative effort between Department of Urology, Department of Pathology and Institute of Cancer Research. The research environment is organized into a clinical research team with several associated research groups working at the Institute of Cancer Research. The research team include urologists, pathologists, radiologists, molecular biologist and statisticians. Read more about the Research Group of Urological Molecular Biology and the Prostate Biobank https://www.ous-research.no/tasken/.
Our overarching research focus is to improve prostate cancer care by developing new methods for diagnosis and treatment. Selected ongoing research topics include, but are not limited to, the following; molecular biomarkers for checkpoint inhibitors in metastatic prostate cancer, clonal evolution in prostate cancer, intra-tumoral heterogeneity, prognostic biomarker panels to stratify recurrence after radical prostatectomy, urinary microvesicles as biomarker for prostate cancer, liquid biomarkers to stratify patient treatment and the role of sympathetic nerves in development of treatment-induced prostate cancer.